Spatial distributions of white matter hyperintensities on brain MRI: A pooled analysis of individual participant data from 11 memory clinic cohorts.

"appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 data availability the wmh probability map is published on dataversenl (link available in manuscript). appendix a supplementary data the following are the supplementary data to this article: supplementary data 1 data availability the wmh probability map is published on dataversenl (link available in manuscript). data availability the wmh probability map is published on dataversenl"

"the implementation of rb score 1 2 and lof was published on github (link available in manuscript)."

"Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FB is supported by the NIHR biomedical research center at UCLH. MD received honoraria for lectures from Bayer Vital and Sanofi Genzyme, Consultant for Hovid Berhad and Roche Pharma. RWP received honoraria from GE Healthcare and is co-lead of Neurofilament light consortium. CHS is supported by an Alzheimer's Society Fellowship. The remaining authors have nothing to disclose."

"Funding The Meta VCI Map consortium is supported by Vici Grant 918.16.616 from 10.13039/501100001826ZonMw to GJB. This study was supported by Veni grant (project9150162010055) from ZonMW to JMB. HJK is supported by the Dutch Hearth Foundation project “brainXplain” (03-004-2021-T043). CDC, EFF and PMM were supported by NIA P30 AG10129, P30 AG072972 and U01 AG024904. ADNI data collection and sharing for this project was funded by the 10.13039/100007333Alzheimer's Disease Neuroimaging Initiative (ADNI) (10.13039/100000002National Institutes of Health Grant U01 AG024904) and 10.13039/100000005DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the 10.13039/100000049National Institute on Aging, the 10.13039/100000070National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (https://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. ACE was funded by 10.13039/501100010969Alzheimer Nederland. PRODEM was supported by the 10.13039/501100002428Austrian Science Fund (FWF grants KLI523, P30134, and I2889-B31). The YOAD study was funded by 10.13039/501100002283Alzheimer’s Research UK (ARUK-Network 2012-6-ICE)."